Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Reinilde Heyrman Insider Profile
4 Followers
Reinilde Heyrman, Chief Clinical Dev. Officer at Bellerophon, holds 9.48K shares in Bellerophon (Ticker: BLPH). Most recently, Reinilde Heyrman Bought $1,500 shares of Bellerophon on Feb 23, 2015 for an estimated value of 18.00K.
Reinilde Heyrman has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Reinilde Heyrman's holdings
Insider Roles
Chief Clinical Dev. Officer
Roles that Reinilde Heyrman holds in companies
Most Profitable Insider Trade
The most profitable trade made by Reinilde Heyrman
Reinilde Heyrman's Trading History
List of latest transactions for each holding click on a transaction to see Reinilde Heyrman's performance on stock
You May Also Like
Reinilde Heyrman insider profile FAQ
What is the percentage of profitable transactions made by Reinilde Heyrman?
The percentage of profitable transactions made by Reinilde Heyrman is ―.
What is the average return per transaction made by Reinilde Heyrman?
The average return per transaction made by Reinilde Heyrman is ―.
What stocks does Reinilde Heyrman hold?
Reinilde Heyrman holds: BLPH stocks.
What was Reinilde Heyrman’s latest transaction?
Reinilde Heyrman latest transaction was an Informative Buy of $18.00K.
What was Reinilde Heyrman's most profitable transaction?
Reinilde Heyrman’s most profitable transaction was an Informative Buy of BLPH stock on February 23, 2015. The return on the trade was -77.00%.
What is Reinilde Heyrman's role in Bellerophon?
Reinilde Heyrman's role in Bellerophon is Chief Clinical Dev. Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.